Seaport Therapeutics shares Phase 1 PK data for GlyphAgo at ECNP
Tweet Send to a Friend
Seaport Therapeutics (Nasdaq: SPTX), a clinical-stage neuropsychiatric drug developer and founded entity of PureTech Health (LSE: PRTC), presented Phase 1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




